CAMP Phase I SYNGAP1 trial authorized to start in Q4
CAMP’s upcoming Phase I SYNGAP1 trial in multiple countries is authorized to begin in Q4. The multi-cohort study will use preclinical and natural history data, with endpoints across cognitive, motor and seizure domains.